There has been considerable interest in the development of new anti tubercular agents particularly against multidrug resistance and extensively drug resistant strain of tuberculosis because mycobacterium species have developed resistant against currently used drugs. The currently use antitubercular drugs having toxic effect and long period of therapeutic treatment. Therefore, many researchers have synthesized various newer drugs and analogues of currently used drugs for tuberculosis treatment. These observations have been guiding for the development of newer analogues that possess potent antitubercular activity with minimum side effects with effectiveness against multidrug resistant mycobacterium , and also in patient co-infected with HIV/AIDS. In this review we are discussed about isoniazid and it analogues as potent antitubercular agents.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
- The author must submit Copyright form After acceptance of the article.